Interferon beta treatment for multiple sclerosis: persisting questions

Abstract

Doctors Noteworthy and Summerfield have reviewed the results of placebo-controlled, double-masked, clinical trials of interferon beta-1b (IFNB-1b, Betaseron) and interferons beta-1a (IFNB-1a, Avonex,) in patients with relapsing multiple sclerosis (MS). IFNB-1b, administered subcutaneously every other day to ambulatory patients with relapsing-remitting MS, significantly reduces annual exacerbation rate and percentage change from baseline MRI T2-weighted total lesion area.^1-4 There is also evidence that IFNB-1b reduces the number of new gadolinium-enhancing lesions in patients with relapsing-remitting MS.⁵ IFNB-1a (Avonex), administered intramuscularly every week to patients with relapsing MS, significantly reduces annual exacerbation rate, the number and volume of new focal gadolinium-enhanced T1-weighted lesions, and slows the accumulation of physical disability over time.⁶ However, questions remain regarding the efficacy of these treatments, the significance of neutralizing antibody formation, indications for therapy, adverse events, optimal dose, and route of administration. Design limitations of the Phase III trial of IFNB-1b have been reviewed elsewhere, ⁷ and a critical review of the results of the Phase III trial of IFNB-1a should be undertaken after the publication of the clinical and imaging results of that study.

Keywords

multiple sclerosis interferon beta neutralizing antibodies

Get full access to this article

View all access options for this article.

References

1 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group . (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized trial. Neurology 45: 1277–1285.

2 The IFNB Multiple Sclerosis Study Group . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized double-blind, placebo-controlled trial. Neurology 43: 655–661.

3 Paty DW et al. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667.

4 Sibley WA et al. (1994) Interferon beta treatment of multiple sclerosis [reply to letters]. Neurology 44: 188–190.

5 Stone LA . (1995) The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37: 611–619.

6 Jacobs L et al. (1994) Biogen's IFN beta-1a reduces progression of disability in multiple sclerosis. First European Presentation of Phase III Trial Results. Clin Courier 12: 1–4.

7 Goodkin DE . (1994) Interferon beta-1b. Lancet 344: 1057–1060.

8 Kurtzke JF . (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452.

9 Kurtzke JF . (1956) Course of exacerbations of multiple sclerosis in hospitalized patients. Arch Neurol Psychiatry 76: 175–184.

10.

10 Neilley LK et al. (1996) Side effect prof ile of interferon beta-1b inmultiple sclerosis: results of an open label trial. Neurology 46: 552–554.

11.

11 McFarland HF et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758–766.

12.

12 Polman CH . (1995) Interferon beta-1b in the treatment of secondary progressive multiple sclerosis. Multiple Sclerosis 1; S51–S54.

13.

13 Sandberg-Wollheim M et al. (1995) Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis 1: S48–S50.

14.

14 Comi G et al. (1995) Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta); design of the study. Multiple Sclerosis 1: S24–S27.

15.

15 Beck RW . (In press) Strategies to delay the onset of clinically definite MS in patients with monosympto-matic presentations of optic neuritis, brainstem syndromes, or myelopathy. In Multiple Sclerosis: Advances in clinical trial design, treatment and future perspectives Eds: Goodkin DE , Rudick RA. Springer-Verlag, London.

16.

16 Rudick RA et al. (1995) Toxicity of recombinant intramuscular interferon-β-1a in multiple sclerosis patients. Ann Neurol 38: 313.

17.

17 Rudge P et al. (1995) Does interferon beta cause initial exacerbations of multiple sclerosis? Lancet 345: 580.